跳至主要内容
临床试验/NCT06513156
NCT06513156招募中不适用

Continuum of Care in Hospitalized Patients With Opioid or Stimulant Use Disorder and Infectious Complications of Drug Use - Substance Use/ID Integrated Clinic vs. TAU to Prevent Infection Related Readmission

Elana Rosenthal8 个研究点 分布在 1 个国家目标入组 304 人开始时间: 2024年10月1日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
304
试验地点
8
主要终点
Infection Rehospitalization

研究概览

简要总结

This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.

详细描述

This is a phase III two arm randomized controlled trial to determine the impact and Integrated infectious diseases (ID) and Substance Use Disorder outpatient clinic (IC) compared to treatment as usual on infection related rehospitalization in individuals hospitalized with infections due to injecting opioids or Stimulants, in the 6 month time period after discharge. This study includes both cost effectiveness and implementation outcomes.

(1) IC will provide facilitated linkage to a clinic providing medical treatment aimed at treating substance use disorder (SUD), resolving the index infection, treating existing ID complications of OUD (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and medication for OUD (MOUD) treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and MOUD providers.

The study will recruit patients during hospitalization for an infection due to injecting opioids or stimulants at four hospital systems (five hospitals) and randomly assign approximately 304 inpatients in 1:1 ratio to IC vs TAU.

Participants will be followed for 12 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Admitted to study hospital (defined as hospitalized with a primary team that is not Emergency Medicine)
  • Injection opioid or stimulant use in past 90 days - per patient self-report
  • Active suspected or confirmed qualifying infection (see list) at time of admission.
  • Qualifying infections:
  • Non-vertebral osteomyelitis
  • Vertebral osteomyelitis or discitis
  • Epidural, subdural, or extradural abscess
  • Intracranial or intraspinal abscess
  • Native joint septic arthritis
  • Prosthetic joint septic arthritis
  • Blood stream infection (bacterial or fungal)
  • Native valve Endocarditis
  • Prosthetic valve endocarditis
  • Cardiac Implantable electronic device infection
  • Infectious pseudoaneurysm and aneurysm
  • Infected vascular graft
  • Septic venous thrombosis
  • Skin and Soft tissue infection (cellulitis, skin abscess, necrotizing fasciitis)
  • Infected skin ulcer
  • Orthopedic hardware infection
  • Muscle abscess/myositis
  • Central nervous system infection (bacterial or fungal)
  • Bacterial or fungal ophthalmologic infection
  • Other abscess
  • Pulmonary septic emboli
  • Other acute bacterial or fungal infection deemed appropriate by site study team

排除标准

  • 1. Infection due to a cause other than injection drug use, per determination of a site PI.
  • 2. Inability to provide consent due to circumstance (e.g., sedated, intubated), language, or cognitive impairment.
  • 3. Unwilling to provide informed consent
  • Unable to receive potential interventions due to geography
  • On comfort measures or planned for discharge to hospice care
  • Incarcerated at the time of hospitalization
  • Other criteria at the discretion of the site investigator

结局指标

主要结局

Infection Rehospitalization

时间窗: 6 months after discharge for index hospitalization

New hospitalization due to infection following discharge for index hospitalization

次要结局

  • Time to first infection related readmission(12 months after discharge for index hospitalization)
  • Reason for infection related readmission(12 months after discharge for index hospitalization)
  • Hospital services utilization(12 months after discharge for index hospitalization)
  • Mortality(12 months after discharge for index hospitalization)
  • Index infection(3 months after discharge for index hospitalization)
  • Other Infections(12 months after discharge for index hospitalization)
  • Skin and soft tissue wounds(12 months after discharge for index hospitalization)
  • New infections not requiring hospitalization(12 months after discharge for index hospitalization)
  • Outpatient linkage and retention(12 months after discharge for index hospitalization)
  • Medication for Opioid Use (MOUD)(12 months after discharge for index hospitalization)
  • Medication for stimulant use (MStUD)(12 months after discharge for index hospitalization)
  • Substance Use-Opioid(12 months after discharge for index hospitalization)
  • Substance Use - Stimulant(12 months after discharge for index hospitalization)
  • Cost Effectiveness(12 months after discharge for index hospitalization)

研究者

发起方
Elana Rosenthal
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Elana Rosenthal

Associate Professor

University of Maryland, Baltimore

研究点 (8)

Loading locations...

相似试验